Objective: To explore the influence of the 2019 edition of National Basic Medical Insurance, Employment Injury Insurance and Maternity Insurance Drug Directory (hereinafter referred to as the Drug Directory) on the management of drug use in hospitals and the ways and methods to strengthen the management of drug use. Methods: The differences between the 2019 edition and the 2017 edition were compared, the characteristics and changes of the 2019 edition were analyzed, and suggestions on how to strengthen the medication management of the hospital after the adjustment of the Drug Directory were put forward. Results: There were a total of 2,643 varieties in the routine access part of the 2019 edition, 150 varieties were transferred out and 148 varieties were transferred in based on the 2017 edition, and 97 varieties were successfully negotiated and included in the list. After the adjustment, the drug structure has undergone great changes, and the scope of payment is more precise, which is conducive to the optimization of hospital drug structure, the standardization of drug use management and the reduction of the burden of insured patients. Conclusion: Hospital pharmacy, medical insurance, medical administration and other departments should form a linkage, strengthen the management of medical insurance drug use, promote rational clinical drug use, accelerate the construction of intelligent medical insurance audit system, and ensure the implementation of the Drug Directory.
Xu Weiquan, Li Yan
. Discussion on the Strategy of Hospital Medication Management Based on the Changes of Medical Insurance Drug Catalogue in 2019[J]. Chinese Pharmaceutical Affairs, 2020
, 34(10)
: 1209
-1213
.
DOI: 10.16153/j.1002-7777.2020.10.013
[1] 薛慧颖,喻兆阳,李娟.2019年版《国家基本医疗保险、工伤保险和生育保险药品目录》解读[J].医药导报,2020,39(1):1-9.
[2] 国家医疗保障局.国家医保局人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录》的通知[EB/OL].(2019-08-20)[2020-08-09].http://www.nhsa.gov.cn/art/2019/8/20/art_37_1666.html.
[3] 国家医疗保障局.国家基本医疗保险、工伤保险和生育保险药品目录解读[EB/OL].(2019-08-22)[2020-08-09].http://www.nhsa.gov.cn/art/2019/8/22/art_38_1677.html.
[4] 王乔宇,赵志刚.2017版《国家基本医疗保险、工伤保险和生育保险的药品目录》与旧版目录的对比及思考 [J].药品评价,2017,14(20):8-18.
[5] 刘金玉,李冬艳,杨光洁,等.2017年版《国家医保药品目录》解读[J].医药导报,2018,37(1):6-12.
[6] 卢琳,马满玲.我国重点监控药品现状分析与思考[J].临床药物治疗杂志,2019,17(10):76-81.
[7] 高楠,徐伟.2017版国家医保药品目录限定支付情况分析[J].中国卫生经济,2018,37(1):48-50.
[8] 中国政府网.国家医保局、人力资源社会保障部印发2019年国家医保谈判准入药品名单[EB/OL].(2019-11-28)[2020-08-09].http://www.gov.cn/xinwen/2019-11/28/content_5456660.htm.
[9] 中国医疗保险研究会.2019年国家医保药品谈判结果出炉呈五大亮点创历史[J].中国医疗保险,2019,(12):彩页4.
[10] 北京市人民政府.关于调整本市基本医疗保险、工伤保险和生育保险药品报销范围有关问题的通知[EB/OL].(2019-12-26)[2020-08-09].http://www.beijing.gov.cn/zhengce/gfxwj/201912/t20191227_1521269.html.
[11] 江西省人民政府.江西省医疗保障局江西省人力资源和社会保障厅关于全面执行《国家基本医疗保险、工伤保险和生育保险药品目录》的通知[EB/OL].(2020-01-09)[2020-08-09].http://www.jiangxi.gov.cn/art/2020/1/9/art_21221_1388311.html?xxgkhide=1.
[12] 湖北省医疗保障局.省医疗保障局省人力资源和社会保障厅关于做好《国家基本医疗保险、工伤保险和生育保险药品目录》实施工作的通知[EB/OL].(2019-12-31)[2020-08-09].http://ybj.hubei.gov.cn/fbjd/xxgkml/zcwj/gfwj/201912/t20191231_1822029.shtml.
[13] 张笑雨.新版《医保药品目录》落地几成[J].中国药店,2020,(2):46-47.
[14] 葛龙,齐新红,王月,等.基于医保规则下的常态化医保智能审核现状[J].中西医结合心血管病电子杂志,2017,5(4):12-14.
[15] 冀召帅,宋微微,艾超.处方前置审核模式的实践与评价[J].中国医院药学杂志,2018,38(16):1743-1746.